Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 pm ET. A live webcast will be available on their website, with a replay archived for 30 days. Theravance focuses on developing innovative respiratory medicines, including the FDA-approved YUPELRI® for COPD. The company also has an economic interest in future payments from Glaxo Group Limited related to certain programs, including TRELEGY.

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42^nd Annual Health Care Conference on Tuesday, March 8, at 2:10 pm ET (11:10 am PT/7:10 pm GMT).

A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.

In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.

Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301486044.html

SOURCE Theravance Biopharma, Inc.

FAQ

What is the date and time of Theravance Biopharma's participation at the Cowen 42nd Annual Health Care Conference?

Theravance Biopharma will participate on March 8, 2022, at 2:10 pm ET.

Where can I watch the webcast of Theravance Biopharma's event?

The webcast can be accessed on Theravance's website under the Investors section, Presentations and Events.

How long will the replay of Theravance Biopharma's conference be available?

The replay of the webcast will be archived for 30 days.

What is the focus of Theravance Biopharma's business?

Theravance Biopharma primarily focuses on discovering and developing respiratory medicines.

What is YUPELRI® and what condition does it treat?

YUPELRI® is an FDA-approved inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD).